February 12, 2009 - Sanofi-aventis said yesterday the ATHENA trial was published in the New England Journal of Medicine, which shows its drug Multaq (dronedarone), in addition to standard therapy, significantly reduced the risk of first cardiovascular hospitalization or death by 24 percent in patients with atrial fibrillation (AF)/atrial flutter (AFL) or a recent history of these conditions.
